Navamin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-01-2025
- Paid Up Capital ₹ 1.00 M
as on 08-01-2025
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 3.75 Cr
as on 08-01-2025
- Satisfied Charges ₹ 7.50 M
as on 08-01-2025
- Revenue %
(FY 2019)
- Profit 102.75%
(FY 2019)
- Ebitda -186.01%
(FY 2019)
- Net Worth 3.44%
(FY 2019)
- Total Assets 596.79%
(FY 2019)
About Navamin Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.75 Cr. The company has closed loans amounting to ₹7.50 M, as per Ministry of Corporate Affairs (MCA) records.
Donapadmanabha Venkatesan and Dona Latha serve as directors at the Company.
- CIN/LLPIN
U74995TN2017PTC118910
- Company No.
118910
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2017
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Navamin Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Donapadmanabha Venkatesan  | Managing Director | 04-Oct-2017 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dona Latha | Director | 04-Oct-2017 | Current |
Financial Performance of Navamin Pharmaceuticals.
Navamin Pharmaceuticals Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 102.75% increase in profit. The company's net worth moved up by a moderate rise of 3.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Navamin Pharmaceuticals?
In 2019, Navamin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 23 Jul 2018 | ₹3.75 Cr | Open |
Canara Bank Creation Date: 02 Jun 2020 | ₹4.00 M | Satisfied |
Canara Bank Creation Date: 04 Apr 2020 | ₹3.50 M | Satisfied |
How Many Employees Work at Navamin Pharmaceuticals?
Unlock and access historical data on people associated with Navamin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Navamin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Navamin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
